How Does Fayuvi Gene Therapy Work?

Fayuvi gene therapy represents a major advance for adults with hemophilia B, a genetic condition caused by a deficiency of clotting Factor IX. Rather than managing bleeding episodes with regular infusions of clotting factor concentrates, Fayuvi offers a one-time treatment designed to address the underlying genetic defect. Below, we explain how Fayuvi works, what to expect before and after treatment, and key considerations for anyone exploring this option.

What Is Fayuvi?

Fayuvi (etranacogene dezaparvovec-drlb) is a gene therapy approved for adults with severe hemophilia B who do not have circulating inhibitors to Factor IX. It uses a harmless viral vector to deliver a functional copy of the Factor IX gene to liver cells, enabling those cells to produce the missing clotting protein. Over time, many patients achieve sustained increases in their own Factor IX levels and see a drastic reduction in bleeding episodes.

How Gene Therapy Works

1. Vector Selection

   • Fayuvi employs an adeno-associated virus serotype 5 (AAV5) vector.
   • AAV5 is non-pathogenic in humans and has been modified to carry the therapeutic gene without causing disease.

2. Therapeutic Gene

   • The vector carries a DNA sequence encoding a high-activity variant of Factor IX (the “Padua” variant), which functions efficiently even at lower protein levels.

3. Delivery to the Liver

   • After intravenous infusion, the vector travels through the bloodstream and homes in on liver cells (hepatocytes).
   • Hepatocytes are the body’s natural site for producing clotting factors.

4. Gene Expression

   • Once inside a liver cell, the AAV5 vector releases its DNA payload into the cell’s nucleus.
   • The nucleus reads the new Factor IX gene and begins manufacturing the Padua variant of the protein.

5. Sustained Protein Production

   • Treated liver cells continue to produce Factor IX over time.
   • Most patients see stable factor levels that reduce or eliminate the need for regular Factor IX infusions.

Who Is Eligible for Fayuvi?

• Adults (18 years or older) diagnosed with severe hemophilia B (Factor IX activity ≤ 2%).
• No history of neutralizing antibodies against AAV5 (assessed by a simple blood test).
• No active liver disease (e.g., hepatitis B or C, uncontrolled liver enzymes).
• No current inhibitors to Factor IX.

Preparing for Fayuvi Treatment

1. Comprehensive Evaluation

   • Medical history, physical exam, and baseline labs (Factor IX activity, liver panel, viral serologies).
   • Assessment of AAV5 antibody status.

2. Liver Health Optimization

   • Control alcohol intake.
   • Manage any existing liver conditions.

3. Medication Review

   • Some immunosuppressive drugs may be needed before and after infusion to help the vector work effectively.
   • Your doctor will discuss any adjustments to current treatments.

4. Informed Consent

   • Understanding potential benefits and risks.
   • Discussion of follow-up schedule and monitoring plan.

What to Expect During Treatment

• Infusion Day

  • A single intravenous infusion over approximately 60 minutes.
  • Performed in an outpatient setting at a specialized infusion center or hospital.

• Immediate Monitoring

  • Observation for acute reactions (e.g., fever, chills, infusion-related discomfort).
  • Vital signs monitored before, during, and after infusion.

Monitoring and Follow-Up

After treatment, you’ll work closely with your hemophilia care team to track:

• Factor IX Activity Levels

  • Measured weekly initially, then monthly once levels stabilize.

• Liver Function Tests

  • To detect any liver inflammation or injury.

• Inhibitor Testing

  • To ensure no new antibodies develop against Factor IX.

• Bleeding Episodes

  • Documentation of any bleeds, their severity, and treatments used.

Most patients see a reduction in bleed rate within the first few months. Continued follow-up for at least three years is generally recommended to ensure safety and sustained efficacy.

Potential Benefits

• Significant reduction or complete elimination of spontaneous bleeds
• Fewer or no regular Factor IX infusions, freeing up time and reducing infusion-related hassles
• Improved joint health and overall quality of life
• Durable therapeutic effect, often lasting years after a single infusion

Possible Risks and Side Effects

While many patients tolerate Fayuvi well, it’s important to be aware of potential issues:

• Liver Enzyme Elevations

  • Mild to moderate increases in liver enzymes are common and usually managed with a short course of steroids.

• Immune Response

  • Rarely, the body may mount an immune reaction against the viral vector or the new Factor IX protein. Immunosuppressive therapy can help control this.

• Infusion-Related Reactions

  • Fever, headache, or fatigue during or shortly after infusion.

• Long-Term Unknowns

  • Gene therapy is relatively new; long-term outcomes are still being studied.

Your hemophilia team will guide you through risk mitigation strategies and close monitoring to address any concerns early.

Realistic Expectations

• Fayuvi is not a cure but a long-lasting treatment that can transform daily life for many people with hemophilia B.
• Some patients reach near-normal Factor IX levels and experience almost no bleeds. Others achieve moderate factor increases that still significantly improve bleeding control.
• Results can vary depending on individual factors like liver health and pre-existing antibodies.

Next Steps and Resources

If you or a loved one are considering Fayuvi:

• Discuss eligibility and timing with your hemophilia specialist.
• Consider comprehensive education about gene therapy, including potential benefits, risks, and the commitment to follow-up care.
• For any symptoms or concerns before or after treatment, you might try a free, online symptom check, using the doctor approved Ubie Symptom Checker.
• Remember, this information is not a substitute for professional medical advice. Always speak to a doctor if you experience serious or life-threatening symptoms.

---

Talk to Your Doctor
Gene therapy options like Fayuvi represent an exciting frontier, but every treatment decision should be made in partnership with your healthcare team. If you have questions about bleeding, joint pain, or possible complications, reach out to your hemophilia care center or primary physician right away.